Abstract

Objectives: Thoracic aortic aneurysms (TAAs) are associated with protein coding variants in genes associated with Loeys-Dietz Syndrome (LDS), vascular Ehlers-Danlos Syndrome (VEDS) and ACTA2 . The purpose of this study was to estimate the prevalence of these variants, along with potential novel variants, in a large unselected clinical population. Methods: We analyzed exome sequence data from 174,452 participants. Rare variants (frequency <0.001) were annotated by functional consequence and classification as pathogenic or likely pathogenic (P/LP) in the ClinVar database. TAA diagnoses were determined by ICD-10 codes. Results: 2,670 (1.5%) individuals had a TAA diagnosis; mean age was 66.1 years, compared to 56.7 for the study population (p=0.014). 69% of TAA cases were male and 71% were smokers. There were 20 carriers of ClinVar P/LP variants in LDS genes (8 variants in 10 carriers for SMAD3 , 3 variants in 3 carriers for TGFB2 , 2 variants in 2 carriers for TGFBR1 , 3 variants in 5 carriers for TGFBR2); 5 had a diagnosis of TAA (2 for SMAD 3, 1 each for the others; ORs =16-65); the age of diagnosis was significantly lower than for non-carriers (p<0.0001). 11 P/LP carriers without a TAA diagnosis were <55 years old and could be at risk for TAA. There was 1 TAA case in 21 COL3A1 P/LP carriers and 0 cases in 10 COL1A1 P/LP carriers. We also identified LDS and VEDS variants that are classified as uncertain significance that could be reclassified as P/LP based on their association with early TAA (Table 1). ACTA2 P/LP variants were also strongly associated with TAA (OR=26; p<0.001). The prevalence of P/LP variants in these genes is 1/3,300 (1/1,350 if potential novel pathogenic variants are included). Conclusions: Our results provide estimates of the prevalence and penetrance of variants associated with TAA in a large unselected clinical population, reveal potential novel pathogenic variants, and support the use of genetic data to identify individuals with high disease risk.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.